Coronary artery disease Circulatory System
Conditions
Interventions
The prospective observation trial included all patients undergoing PCI and requiring dual antiplatelet therapy for 12 months. The prospective genotype-guided strategy (intervention group) will be comp
Sponsors
Qatar Precision Health Institute
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients older than 18 years 2. Written consent from the patient or legally acceptable representative (LAR) 3. Indication for PCI 4. Require an antiplatelet therapy
Exclusion criteria
Exclusion criteria: 1. Major bleeding 2. Contraindication to the use of antiplatelet therapy 3. Pregnant females 4. Participating in other clinical trials on a medicinal product or blood donation for less than 3 months 5. Liver cirrhosis 6. Bone marrow transplantation 7. Advanced malignancy 9. Severe thrombocytopenia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Cardiovascular death: death from any cardiovascular cause or death not clearly attributable to a non-cardiovascular cause assessed using medical records within 1 year 2. ACS: diagnosis of acute myocardial ischemia (STEMI, non-STEMI) or unstable angina assessed using medical records within 1 year 3. Non-fatal stroke: neurological deficit of 24 hours or more with confirmation by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) within 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Rehospitalization and length of stay in the hospital recorded in electronic medical records (EMR) within 1 year 2. Markers of stent thrombosis or coronary ischemic event not related to stent thrombosis recorded in electronic medical records (EMR) within 1 year | — |
Countries
Qatar
Contacts
Public ContactRania Abdellatif
Outcome results
None listed